← Eichor
Condition: Relapsed Refractory Multiple Myeloma Mm Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Relapsed Refractory Multiple Myeloma Mm

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treatin
EARLY_Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07101705All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06158412A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Phase 1/Phase 2 · 104 location(s) · Sumitomo Pharma America, Inc. · NCT04988555Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-
Phase 1 · 8 location(s) · Newave Pharmaceutical Inc · NCT04771572A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidos
Phase 1/Phase 2 · 20 location(s) · Regeneron Pharmaceuticals · NCT06292780A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multipl
EARLY_Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07429721Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
Phase 1/Phase 2 · 1 location(s) · Xuzhou Medical University · NCT06196255Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies
Phase N/A · 1 location(s) · Sung-Soo Park · NCT07051850Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma
Phase 1 · 1 location(s) · Xi'an No.3 Hospital · NCT07139509MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Ha
Phase 3 · 271 location(s) · Pfizer · NCT06152575A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
Phase 1/Phase 2 · 11 location(s) · IDP Discovery Pharma S.L. · NCT05908409A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Partic
Phase 1 · 14 location(s) · Genentech, Inc. · NCT05927571A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Phase 2 · 2 location(s) · Oncotherapeutics · NCT06115135A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in
Phase 1 · 2 location(s) · David Avigan · NCT06799026To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL
EARLY_Phase 1 · 1 location(s) · Hrain Biotechnology Co., Ltd. · NCT06045091Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
Phase 1 · 1 location(s) · Beijing GoBroad Hospital · NCT07003568Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
Phase 1 · 1 location(s) · Beijing GoBroad Hospital · NCT07003555Universal CAR-T Cell Therapy for MM
NA · 1 location(s) · Bioray Laboratories · NCT07248176Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma
Phase 1 · 1 location(s) · Hadassah Medical Organization · NCT07333430Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
Phase 2 · 2 location(s) · Hrain Biotechnology Co., Ltd. · NCT05594797Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
Phase 1/Phase 2 · 7 location(s) · YOUNGIL KOH · NCT06645678Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
NA · 1 location(s) · Anhui Provincial Hospital · NCT06961669Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
NA · 1 location(s) · 920th Hospital of Joint Logistics Support Force of People's · NCT06515262ELISA in Relapsed/Refractory MM
Phase 2 · 3 location(s) · Massachusetts General Hospital · NCT06832865Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
Phase 1/Phase 2 · 3 location(s) · Omar Nadeem, MD · NCT06518551Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
Phase 1/Phase 2 · 1 location(s) · Xuzhou Medical University · NCT06759181LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
NA · 4 location(s) · Nanjing Legend Biotech Co. · NCT07100067A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myelom
Phase 1 · 20 location(s) · C4 Therapeutics, Inc. · NCT07280013A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Phase 1/Phase 2 · 10 location(s) · ModernaTX, Inc. · NCT07116616
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.